Results 91 to 100 of about 43,347 (262)

Cystatin from the helminth Ascaris lumbricoides upregulates mevalonate and cholesterol biosynthesis pathways and immunomodulatory genes in human monocyte-derived dendritic cells

Frontiers in Immunology
BackgroundAscaris lumbricoides cystatin (Al-CPI) prevents the development of allergic airway inflammation and dextran-induced colitis in mice models. It has been suggested that helminth-derived cystatins inhibit cathepsins in dendritic cells (DC), but ...
Nathalie Acevedo, Ana Lozano, Josefina Zakzuk, Kevin Llinás-Caballero, David Brodin, Peter Nejsum, Andrew R. Williams, Luis Caraballo   +7 more
doaj   +1 more source

Increased Cystatin C in Astrocytes of Transgenic Mice Expressing the K670N-M671L Mutation of the Amyloid Precursor Protein and Deposition in Brain Amyloid Plaques

Neurobiology of Disease, 2001
Cystatin C is an essential secretory cofactor for neurogenesis with potent protease inhibitor activities. Polymorphisms of cystatin C are genetically associated with Alzheimer's disease (AD), and the L68Q mutation causes hereditary cerebral hemorrhage ...
Tiana Steinhoff, Eva Moritz, M.Axel Wollmer, M.Hasan Mohajeri, Stefan Kins, Roger M. Nitsch   +5 more
doaj   +1 more source

TREM2 in Macrophages Promotes Renal Fibrosis via Activation of β‐Catenin Signalling Pathway in Obstructive Nephropathy

Cell Proliferation, EarlyView.
Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) promotes obstructive nephropathy progression by activating the β‐catenin signalling pathway, driving M2 macrophage polarisation, migration and fibrogenic gene expression. targeted inhibition of TREM2 thus represents a promising novel strategy against renal fibrosis.
Jia Wei, Zixia Li, Gengyu Du, Ting Chen, Min Yang, Zhen Yuan, Yidan Zheng, Xiang Yan   +7 more
wiley   +1 more source

[Cystatin C and cardiovascular risk.

, 2010
Patients with chronic kidney disease (CKD) are at high risk for developing cardiovascular disease (CVD) and cardiovascular events. Cystatin C, a protease inhibitor synthesized in all nucleated ceils, has been proposed as a replacement for serum ...
TAGLIERI, NEVIO, Koenig W, Kaski JC
core   +1 more source

Oxidative Stress Drives Cell Cycle Stalling, Apoptosis and Metabolic Suppression in Cystatin B Deficient EPM1 Patient iPSCs

Cell Proliferation, EarlyView.
CSTB deficient EPM1 iPS cells manifest increased lysosomal activity and oxidative stress, which lead to DNA damage, cell cycle defects and increased apoptosis. As a protective response, metabolism is suppressed. Image created by BioRender https://BioRender.com/t44oc6h.
Shekhar Singh, Lidiia Plotnikova, Teemu Tiukuvaara, Reetta Kälviäinen, Riikka H. Hämäläinen   +4 more
wiley   +1 more source

Kadar Cystatin-C Serum Sebagai Penanda Fungsi Ginjal Bayi Prematur

Sari Pediatri, 2016
Latar belakang. Cystatin-C dipertimbangkan menjadi pemeriksaan potensial pengganti kreatinin serum sebagai penanda fungsi ginjal. Kadar cystatin-C serum lebih mendekati nilai laju filtrasi glomerulus dibandingkan dengan kreatinin serum.
Dinna Meinardaniawati, Sjarif Hidajat Effendi, Sri Endah Rahayuningsih   +2 more
doaj   +1 more source

Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Empagliflozin is renoprotective in Type 2 diabetes mellitus (T2DM). Our primary aim was to assess empagliflozin's effect on glomerular filtration rate and renal vascular resistance using multiparametric MRI (MpMRI). Our secondary aim was to assess the impact of empagliflozin on additional MpMRI‐derived metrics including markers of tissue ...
Ruth P. Lim, Salma Qassin, Lucy McKenna, Emma Hornsey, Dominic Italiano, Leonid Churilov, Richard J. MacIsaac, Jas‐mine Seah, Elif I. Ekinci, The Austin EMPA‐MRI Study Group   +9 more
wiley   +1 more source

Exercise electrocardiographic responses and serum cystatin C levels among metabolic syndrome patients without overt diabetes mellitus

, 2011
Asli Tanindi1 Hilal Olgun1 Ayse Tuncel2 Bulent Celik3 Hatice Pasaoglu2 Bulent Boyaci11Department of Cardiology, 2Department of Medical Biochemistry, Faculty of Medicine, 3Department of Statistics, Faculty of Health Sciences, Gazi University, Ankara ...
Tanindi A, Tuncel AF, Pasaoglu H, Olgun, Boyaci B, CELIK B   +5 more
core  

Inhibition of cysteine peptidase activity in ascitic fluid in pancreatic cancer patients

Folia Histochemica et Cytobiologica, 2010
The work's objective is to answer the question whether there is any possibility of activity inhibition of cysteinepeptidases inhibitors playing an important role in key processes accompanying cancer formation, including pancreas.
Anil Kumar Agrawal, Wojciech Kielan, Abdo Katib, Zygmunt Grzebieniak, Adam Skalski, Tomasz Grzebieniak, £ukasz Duda-Barcik, Anna Janocha, Maciej Siewiñski   +8 more
doaj  

Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Orforglipron is a novel small‐molecule, once daily oral non‐peptide GLP‐1 receptor agonist. The hepatic safety profile in adults with obesity or overweight and/or type 2 diabetes (T2D) across seven orforglipron Phase 3 clinical trials was assessed.
Sean Wharton, Adam Stefanski, Jiaxun Chen, Girish Rao, Elvis Asare Twum, Max Denning   +5 more
wiley   +1 more source